News | April 02, 2024
Viatris launches RYZUMVl 0.75% in US
The average time of dilation lasts three to eight hours
The average time of dilation lasts three to eight hours
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
This agreement paves the way for the introduction of YESAFILI into the Canadian market
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The company has received five final approvals
The product is expected to be launched in December 2023
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Subscribe To Our Newsletter & Stay Updated
